Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Novocure

< Previous 1 2 3 Next >
Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023
From Novocure
Via Business Wire
Tickers NVCR
Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Report Third Quarter 2023 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting
From Novocure
Via Business Wire
Tickers NVCR
Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
From Novocure
Via Business Wire
Tickers NVCR
Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Participate in Upcoming Investor Conferences
From Novocure
Via Business Wire
Tickers NVCR
Novocure Reports Second Quarter 2023 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Report Second Quarter 2023 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
From Novocure
Via Business Wire
Tickers NVCR
Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
From Novocure
Via Business Wire
Tickers NVCR
Novocure Reports First Quarter 2023 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Report First Quarter 2023 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
Kristin Stafford Joins Novocure Board of Directors
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Tickers NVCR
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Tickers NVCR
Allyson J. Ocean, M.D., Joins Novocure Board of Directors
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Organizational Changes to Prepare for Future Growth
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference
From Novocure
Via Business Wire
Tickers NVCR
Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
From Novocure
Via Business Wire
Tickers NVCR
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.